Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $37.87 and last traded at $37.86, with a volume of 12029 shares. The stock had previously closed at $33.99.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. TD Cowen assumed coverage on shares of Nanobiotix in a research report on Friday, February 6th. They set a “buy” rating on the stock. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Finally, Guggenheim lifted their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Nanobiotix Stock Performance

The firm’s 50 day moving average is $23.90 and its 200 day moving average is $20.35.

Institutional Trading of Nanobiotix

Several hedge funds and other institutional investors have recently made changes to their positions in NBTX. Royal Bank of Canada raised its stake in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Optiver Holding B.V. purchased a new stake in shares of Nanobiotix in the third quarter worth $101,000. Marshall Wace LLP bought a new position in shares of Nanobiotix during the fourth quarter valued at $220,000. Finally, Millennium Management LLC purchased a new position in shares of Nanobiotix in the 4th quarter worth about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.